252580-08-8

Basic information

• Product Name: 4,5-Oxazoledicarboxylic acid, 4,5-dihydro-2-phenyl-, dimethyl ester, (4S,5S)-
• CAS NO: 252580-08-8
• Molecular Formula: C13H13NO5
• Molecular Weight: 263.25
• Mol File: 252580-08-8.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 4,5-Oxazoledicarboxylic acid, 4,5-dihydro-2-phenyl-, dimethyl ester, (4S,5S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 4,5-Oxazoledicarboxylic acid, 4,5-dihydro-2-phenyl-, dimethyl ester, (4S,5S)-(252580-08-8)
• EPA Substance Registry System: 4,5-Oxazoledicarboxylic acid, 4,5-dihydro-2-phenyl-, dimethyl ester, (4S,5S)-(252580-08-8)

Safety Data

• Hazardous Substances Data: 252580-08-8(Hazardous Substances Data)

Upstream product

• 86555-45-5 (2S)-N-benzoyl-L-aspartic acid dimethyl ester 

Downstream Products

• 15926-44-0 2-phenyl-oxazole-4,5-dicarboxylic acid 
• 1186-90-9 L-threo-3-hydroxyaspartic acid 
• 144946-64-5 2-phenyl-oxazole-4,5-dicarboxylic acid dimethyl ester 
• 252580-10-2 L-(2S,3S)-N-benzoyl-3-hydroxyaspartic acid dimethyl ester 

Relevant articles and documents

SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS

The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

Ring-opening of oxazolines derived from l-serine: a short and efficient stereoselective synthesis of all four diastereomers of 3-mercaptoaspartic acid derivatives

Facile methods are described for accessing four diastereomerically pure 3-mercaptoaspartic acid derivative from l-aspartic acid. In our synthesis, ring-opening reactions of oxazoline-4,5-dicarboxylate with thiolacetic acid as well as the stereochemical interconversion of both α- and β-configuration via oxazoline chemistry were utilized as key steps.

A rational approach to the design of selective substrates and potent nontransportable inhibitors of the excitatory amino acid transporter EAAC1 (EAAT3). New glutamate and aspartate analogues as potential neuroprotective agents

Two three-dimensional receptor interaction models for EAAT substrates and nontransportable inhibitors have been developed, and new glutamate (Glu) and aspartate (Asp) analogues have been synthesized. The analogues 1a and 3 represent novel lead compounds f